Multi Drug Resistant Market is Expected to Reach US$ XX Mn by 2025

30/gen/2019 12:41:08 Rajesh Contatta l'autore

Questo comunicato è stato pubblicato più di 1 anno fa. Le informazioni su questa pagina potrebbero non essere attendibili.

The Multi Drug Resistant Market is anticipated to reach about US$ XX Mn by 2025, and anticipated to expand at a CAGR over seven years of forecast period 2019-2025” owing  to an increase in prevalence of the drug resistant bacterial infections such as multi drug resistant TB.


Precision Business Insights (PBI) in its report titled “Multi Drug Resistant Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis and Forecast 2019-2025” assesses the market performance over seven years forecast period from 2019 to 2025. The report analyses the market value forecast and provides the strategic insights into the market driving factors, challenges that are hindering the market revenue growth over forecast period.


The multi drug resistant market size was accounted for US$ XX Mn in 2018 and anticipated to account for US$ XX Mn by 2025. Increased prevalence of the drug resistant bacterial infections such as multi drug resistant TB. In addition, increase in R&D activities to develop the new generation multi drug resistant antibiotics by the marketers coupled with the government and non-government organization’s initiatives and funding are expected to boost the market growth over the forecast period. Furthermore, recent drug resistance antibiotic approvals and promising pipeline drugs are expected to bolster the multi drug resistant antibiotics market over the forecast period. However, high cost of incurred in R&D and lack of effective antibiotics are expected to hamper the market multi drug resistance antibiotics market during the forecast period.


A sample of this report is available upon request @


Multi drug resistant market segmented on the basis of type of bacteria, disease, and distribution channel.


Beta-Lactam Drug Segment Expected to Dominate the Market


In 2016, Beta Lactam held the largest market share in the drug class segment due to factors such as rising prevalence of multiple drug resistance cases and development of drugs such as Ceftazidime-avibactam and Doripenem which exhibit broad spectrum activity to counteract drug resistance by bacteria.


Retail Pharmacies Will Dominate the Revenue Share.


Based on distribution channel, multi drug resistant drug market segmented into hospital pharmacies, retail pharmacies, and others. The retail pharmacies witnessed to account for major revenue share over the forecast period. The availability of drug over the counter (OTC) accounts for its market growth.   

North America Accounts for Major Revenue Share for Multi Drug Resistant Market


Precision Business Insights (PBI) multi drug resistant market report analyses the market in different regions North America, Europe, Asia Pacific, Latin America and Middle East and Africa. According to regional analysis, North America accounted for major revenue share owing to the factors such as growing awareness and increase in R&D activities in developing the novel drugs for multi drug resistant infections and well-established healthcare infrastructure. Europe market is driven by the increase in prevalence of the multi drug resistant infections and developed healthcare infrastructure. Asia Pacific multi drug resistant market is expected to grow at notable rates owing to low cost of R&D and expansion of the multinational companies into the developing countries such as India.


To view TOC of this report is available upon request @


Recent Advancements Play a Vital Role in Multi Drug Resistant Market


Major players are increasingly expanding their footprint in the emerging nations, competing with key players in the market especially in terms of features such as new product launch, collaborations, mergers, acquisitions and other market strategies. For instance, In August 2017, U.S. FDA approved The Medicines Company’s Vabomere (meropenem and vaborbactam) for adult patients with urinary tract infections, including pyelonephritis. Vabomere also inhibits certain types of resistance mechanisms used by bacteria

Key player’s profiles in the report are F. Hoffmann-La Roche AG, Achaogen Inc., Acetlion Pharmaceuticals, Sanofi S.A, Johnson & Johnson Services Inc., Pfizer Inc., Otsuka Pharmaceutical, and Eli Lilly and Company to name a few.

Need more information about this report @


Detailed Segmentation


By Bacteria Type


  • Multi Drug Resistant Enterococci
  • Multi Drug Resistant Staphylococci
  • Gram Negative
  • Others


By Disease Type


  • Drug Resistant Tuberculosis
  • Others


By Distribution Channel Type


  • Hospital Pharmacies
  • Retail Pharmacies
  • Others




  • North America
  • S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Russia
  • Spain
  • Italy
  • Rest of Europe
  • Asia-Pacific
  • China
  • Japan
  • India
  • Rest of Asia Pacific
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Chile
  • Rest of Latin America
  • Middle East and Africa
  • South Africa
  • Saudi Arabia
  • Rest of MEA



Get access to full summary @



About Precision Business Insights

Precision Business Insights is one of the leading market research and business consulting firm, which follow a holistic approach to solve needs of the clients. We adopt and implement proven research methodologies to achieve better results. We help our clients by providing actionable insights and strategies to make better decisions. We provide consulting, syndicated and customised market research services based on our client needs.

Contact to Precision Business Insights,

Kemp House,

152 – 160 City Road,

London EC1V 2NX

Contact Person: Rajesh Babu

Role: Marketing Lead


Toll Free (US):+1-866-598-1553

Website @


blog comments powered by Disqus è un servizio offerto da Factotum Srl